[
    [
        {
            "time": "",
            "original_text": "A股异动 | 贝达药业(300558.SZ)大涨10% 拟推2021年限制性股票激励计划",
            "features": {
                "keywords": [
                    "贝达药业",
                    "大涨",
                    "限制性股票激励计划"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股异动 | 贝达药业(300558.SZ)大涨10% 拟推2021年限制性股票激励计划",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国盛证券维持贝达药业买入评级：未来五年有望加速增长，股权激励体现公司十足信心",
            "features": {
                "keywords": [
                    "国盛证券",
                    "买入评级",
                    "加速增长",
                    "股权激励"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券维持贝达药业买入评级：未来五年有望加速增长，股权激励体现公司十足信心",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业跟踪报告：创新药系列研究 PD-1/L1普药化 国内IO市场如何演绎",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新药",
                    "PD-1/L1",
                    "普药化",
                    "国内IO市场"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业跟踪报告：创新药系列研究 PD-1/L1普药化 国内IO市场如何演绎",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]